Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Fishman

Showing results (331-340 of 359) with videos related to

Pageof 36
Sort By:
Annals of Internal Medicine|August 1, 1987
Primary pulmonary hypertension. A national prospective studyS Rich, D R Dantzker, S M Ayres, et al.
American Journal of Respiratory and Critical Care Medicine|June 2, 2009
Integrating health status and survival data: the palliative effect of lung volume reduction surgeryRoberto Benzo, Max H Farrell, Chung-Chou H Chang, et al.
Chest|July 22, 2008
Continuous oxygen use in nonhypoxemic emphysema patients identifies a high-risk subset of patients: retrospective analysis of the National Emphysema Treatment TrialMichael B Drummond, Amanda L Blackford, Joshua O Benditt, et al.
Circulation|October 1, 1990
The report of the American Heart Association task force on strategies to increase federal research fundingM R Rosen, H C Strauss, H G Atkinson, et al.
Biochemical Pharmacology|July 8, 2008
The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis ratsA Ochaion, S Bar-Yehuda, S Cohen, et al.
The American Review of Respiratory Disease|December 1, 1989
The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary HypertensionE K Weir, L J Rubin, S M Ayres, et al.
Annals of Internal Medicine|September 1, 1991
Survival in patients with primary pulmonary hypertension. Results from a national prospective registryG E D'Alonzo, R J Barst, S M Ayres, et al.
The Annals of Thoracic Surgery|August 8, 2006
Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research GroupKeith S Naunheim, Douglas E Wood, Zab Mohsenifar, et al.
Arthritis and Rheumatism|October 1, 2009
Induction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatmentS Bar-Yehuda, L Rath-Wolfson, L Del Valle, et al.
American Journal of Respiratory and Critical Care Medicine|March 3, 2022
Signal Transducer and Activator of Transcription 5B Deficiency-associated Lung DiseaseKatie A Krone, Corinne L Foley, Martha P Fishman, et al.
Pageof 36

Showing results (331-340 of 359) with videos related to

Sort By:
Pageof 36
Annals of Internal Medicine|August 1, 1987
Primary pulmonary hypertension. A national prospective studyS Rich, D R Dantzker, S M Ayres, et al.
American Journal of Respiratory and Critical Care Medicine|June 2, 2009
Integrating health status and survival data: the palliative effect of lung volume reduction surgeryRoberto Benzo, Max H Farrell, Chung-Chou H Chang, et al.
Chest|July 22, 2008
Continuous oxygen use in nonhypoxemic emphysema patients identifies a high-risk subset of patients: retrospective analysis of the National Emphysema Treatment TrialMichael B Drummond, Amanda L Blackford, Joshua O Benditt, et al.
Circulation|October 1, 1990
The report of the American Heart Association task force on strategies to increase federal research fundingM R Rosen, H C Strauss, H G Atkinson, et al.
Biochemical Pharmacology|July 8, 2008
The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis ratsA Ochaion, S Bar-Yehuda, S Cohen, et al.
The American Review of Respiratory Disease|December 1, 1989
The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary HypertensionE K Weir, L J Rubin, S M Ayres, et al.
Annals of Internal Medicine|September 1, 1991
Survival in patients with primary pulmonary hypertension. Results from a national prospective registryG E D'Alonzo, R J Barst, S M Ayres, et al.
The Annals of Thoracic Surgery|August 8, 2006
Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research GroupKeith S Naunheim, Douglas E Wood, Zab Mohsenifar, et al.
Arthritis and Rheumatism|October 1, 2009
Induction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatmentS Bar-Yehuda, L Rath-Wolfson, L Del Valle, et al.
American Journal of Respiratory and Critical Care Medicine|March 3, 2022
Signal Transducer and Activator of Transcription 5B Deficiency-associated Lung DiseaseKatie A Krone, Corinne L Foley, Martha P Fishman, et al.
Pageof 36